FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308786265> ?p ?o ?g. }

• W4308786265 endingPage "122386" @default.
• W4308786265 startingPage "122386" @default.
• W4308786265 abstract "In order to highlight the advantages of cocrystallization technique in perfecting in vitro/vivo natures of marine drug cytarabine (ARC), and fill the gap of the research of marine pharmaceutical cocrystals with synergistic antitumor effects, the first dual-drug cocrystal simultaneously containing ARC and antitumor drug 5-fluorouracil (FU), viz. ARC-FU, is successfully designed and assembled. The accurate structure is perfectly resolved by single-crystal X-ray diffraction and other approaches. The analytical outcomes demonstrate that the codrug cocrystal consists of ARC and FU with a molar ratio of 1:1, in which FU molecule plays an important role by participating in the formation of both pyrimidine-pyrimidine and pyrimidine-sugar cyclic hydrogen-bonding systems with ARC molecules. In the cocrystal, there are twofold hydrogen-bonding helixes of ARC molecules and a whole three-dimensional hydrogen-bonding network which also contains the aromatic stacking interaction between pyrimidine rings of both components. Such structural feature and aggregation model have crucial influences on the improvements of in vitro/vivo properties, which is methodically verified by the combination of theoretical analyses and experimental measurements. The in vitro studies exhibit the suitably reduced solubility and obviously increased permeability for the cocrystal that is in accord with the theoretical prediction. Importantly, the ameliorated in vitro peculiarities realize in vivo pharmacokinetic optimization including the extended residence time and enhanced relative bioavailability. Of greater significance, ARC exerts synergistic antitumor effects in association with FU that brings about potentiation of cell growth inhibition with lower IC50. Thus, this research not only provides a novel crystalline form for ARC with forward-looking development value, but also breaks new ground for the development of synergistic antitumor pharmaceutical cocrystals with marine characteristics." @default.
• W4308786265 created "2022-11-15" @default.
• W4308786265 creator A5007093042 @default.
• W4308786265 creator A5013070709 @default.
• W4308786265 creator A5026736738 @default.
• W4308786265 creator A5027789259 @default.
• W4308786265 creator A5048797492 @default.
• W4308786265 creator A5066191593 @default.
• W4308786265 date "2022-12-01" @default.
• W4308786265 modified "2023-10-12" @default.
• W4308786265 title "The first marine dual-drug cocrystal of cytarabine with 5-fluorouracil having synergistic antitumor effects shows superior biopharmaceutical peculiarities by oral administration" @default.
• W4308786265 cites W1539939143 @default.
• W4308786265 cites W1968763546 @default.
• W4308786265 cites W1969360633 @default.
• W4308786265 cites W1973892826 @default.
• W4308786265 cites W1977552239 @default.
• W4308786265 cites W1983032431 @default.
• W4308786265 cites W1990755277 @default.
• W4308786265 cites W1992964622 @default.
• W4308786265 cites W1994344535 @default.
• W4308786265 cites W2000011121 @default.
• W4308786265 cites W2001467312 @default.
• W4308786265 cites W2017229125 @default.
• W4308786265 cites W2024071582 @default.
• W4308786265 cites W2032870044 @default.
• W4308786265 cites W2035034315 @default.
• W4308786265 cites W2050468116 @default.
• W4308786265 cites W2052380980 @default.
• W4308786265 cites W2055222364 @default.
• W4308786265 cites W2061521035 @default.
• W4308786265 cites W2096439168 @default.
• W4308786265 cites W2103562758 @default.
• W4308786265 cites W2132525235 @default.
• W4308786265 cites W2306077232 @default.
• W4308786265 cites W2326434969 @default.
• W4308786265 cites W2326492319 @default.
• W4308786265 cites W2472317901 @default.
• W4308786265 cites W2493265196 @default.
• W4308786265 cites W2552237749 @default.
• W4308786265 cites W2594837965 @default.
• W4308786265 cites W2765384035 @default.
• W4308786265 cites W2766500377 @default.
• W4308786265 cites W2806393666 @default.
• W4308786265 cites W2891058391 @default.
• W4308786265 cites W2893120990 @default.
• W4308786265 cites W2924249867 @default.
• W4308786265 cites W3012262684 @default.
• W4308786265 cites W3025136756 @default.
• W4308786265 cites W3039774048 @default.
• W4308786265 cites W3048802245 @default.
• W4308786265 cites W3105622149 @default.
• W4308786265 cites W3134130267 @default.
• W4308786265 cites W3172044901 @default.
• W4308786265 cites W3190413658 @default.
• W4308786265 cites W4200383061 @default.
• W4308786265 cites W4210687326 @default.
• W4308786265 doi "https://doi.org/10.1016/j.ijpharm.2022.122386" @default.
• W4308786265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36372139" @default.
• W4308786265 hasPublicationYear "2022" @default.
• W4308786265 type Work @default.
• W4308786265 citedByCount "1" @default.
• W4308786265 countsByYear W43087862652023 @default.
• W4308786265 crossrefType "journal-article" @default.
• W4308786265 hasAuthorship W4308786265A5007093042 @default.
• W4308786265 hasAuthorship W4308786265A5013070709 @default.
• W4308786265 hasAuthorship W4308786265A5026736738 @default.
• W4308786265 hasAuthorship W4308786265A5027789259 @default.
• W4308786265 hasAuthorship W4308786265A5048797492 @default.
• W4308786265 hasAuthorship W4308786265A5066191593 @default.
• W4308786265 hasConcept C100687433 @default.
• W4308786265 hasConcept C112887158 @default.
• W4308786265 hasConcept C150903083 @default.
• W4308786265 hasConcept C178790620 @default.
• W4308786265 hasConcept C185592680 @default.
• W4308786265 hasConcept C207001950 @default.
• W4308786265 hasConcept C21951064 @default.
• W4308786265 hasConcept C2779321679 @default.
• W4308786265 hasConcept C32909587 @default.
• W4308786265 hasConcept C71240020 @default.
• W4308786265 hasConcept C86803240 @default.
• W4308786265 hasConceptScore W4308786265C100687433 @default.
• W4308786265 hasConceptScore W4308786265C112887158 @default.
• W4308786265 hasConceptScore W4308786265C150903083 @default.
• W4308786265 hasConceptScore W4308786265C178790620 @default.
• W4308786265 hasConceptScore W4308786265C185592680 @default.
• W4308786265 hasConceptScore W4308786265C207001950 @default.
• W4308786265 hasConceptScore W4308786265C21951064 @default.
• W4308786265 hasConceptScore W4308786265C2779321679 @default.
• W4308786265 hasConceptScore W4308786265C32909587 @default.
• W4308786265 hasConceptScore W4308786265C71240020 @default.
• W4308786265 hasConceptScore W4308786265C86803240 @default.
• W4308786265 hasFunder F4320324174 @default.
• W4308786265 hasLocation W43087862651 @default.
• W4308786265 hasLocation W43087862652 @default.
• W4308786265 hasOpenAccess W4308786265 @default.
• W4308786265 hasPrimaryLocation W43087862651 @default.
• W4308786265 hasRelatedWork W1970350913 @default.
• W4308786265 hasRelatedWork W2000268714 @default.

• next